Recently, immunotherapies using antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have proven to be powerful and effective treatments for patients with various advanced cancers in many clinical trials [27–30]. The gene discussed is PDCD1; the disease is cancer.